CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Ketaminedrug
Likely dose
Ketamine 0.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02078817
NCT02078817Phase 2Completed
CompareCT.gov

Open-Label Intravenous Subanesthetic Ketamine for Adolescents With Treatment-Resistant Depression

University of Minnesota·interventional·Posted Mar 5, 2014·Updated Jan 27, 2020

In Brief

A Phase 2 clinical trial evaluating Ketamine for Major Depressive Disorder. Completed, enrolled 14 participants across 1 site.

Detailed Summary

This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 5, 2014
Enrollment StartSep 1, 2014
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.3 years ago

Interventions

Ketaminedrug

IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.